Novartis investigative Site

Garran, Australian Capital Territory 2606

0 studies enrolling now · 9 studies all time

What they study most

Atherosclerosis, Breast Cancer, Breast Neoplasms, Primary Immune Thrombocytopenia (ITP), Primary Prevention of Atherosclerotic Cardiovascular Disease, Purpura, Thrombocytopaenic, Idiopathic, Warm Autoimmune Hemolytic Anemia (wAIHA)

Studies at this site

• A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. — Running, not enrolling
• A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia — Running, not enrolling
• Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) — Running, not enrolling
• A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies — Running, not enrolling
• Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer — Completed
• Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer — Completed
• Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events) — Completed
• EXTEND (Eltrombopag Extended Dosing Study) — Completed
• Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer — Completed